|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03208894 |
|
Date of registration:
|
01/07/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Role of Salbutamol and Furosemide in TTN
|
|
Scientific title:
|
Role of Salbutamol and Furosemide in Transient Tachypnea of Newborn |
|
Date of first enrolment:
|
November 1, 2016 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03208894 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
Pakistan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- all newborn babies with clinically diagnosed TTN
Exclusion Criteria:
- babies less than 34 weeks babies with congenital malformations and CHD
Age minimum:
N/A
Age maximum:
7 Days
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Transient Tachypnea of the Newborn
|
|
Intervention(s)
|
|
Drug: Furosemide Injection
|
|
Primary Outcome(s)
|
|
duration of oxygen requiremment in neonates having TTN.
[Time Frame: upto 6 months]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|